Dr. Erin Jordan

Field of research

My research interest is to optimize productivity of yeast cell factories through integrated -omics strategies such as genomics, transcriptomics, and metabolomics. While metabolic engineering requires the manipulation of a small number of pathways, it is well known that small perturbations to the cell can result in off-target effects that proliferate throughout the entirety of the cell. These changes include changes to flux, redox balance, energy allocation, and physiological changes to the cell as an adaptation to cell stress. My goal is to uncover these changes as they occur and address the challenges to improve the overall productivity of a metabolically engineered cell.

Jordan, E.N. Behind The Paper: Integrated -Omics of Saccharomyces cerevisiae CENPK2-1C Reveals Pleiotropic Drug Resistance and Lipidomic Adaptations to Cannabidiol, Springer Nature Communities

Jordan, E.N., Shirali Hossein Zade, R., Pillay, S., van Lent, P., Abeel, T., and Kayser, O. Integrated omics of Saccharomyces cerevisiae CENPK2-1C reveals pleiotropic drug resistance and lipidomic adaptations to cannabidiol. npj Syst Biol Appl 2024, 10. DOI:https://doi.org/10.1038/s41540-024-00382-0

Jordan, E.N., Schmidt, C. and Kayser, O. Foldseek reveals a CBGA prenylating enzyme GlyMa_02G168000 from Glycine max. Biochem Biophys Res Commun 2024, DOI: https://doi.org/10.1016/j.bbrc.2024.149471

Jordan, E.N., Nguyen, G.-N., Reynoso-Moreno, I., Gertsch, J., and Kayser, O. Synthesis of stilbenyl and bibenzyl cannabinoids and analysis of their cannabimimetic potential. Synthesis 2024, 56. DOI: 10.1055/s-0042-1751539

Nguyen, G.-N., Jordan, E.N.,  and Kayser, O. Protecting-group-free synthesis of novel cannabinoid-like 2,5-dihydrobenzoxepines. Synthesis 2022, 54, A-K. DOI:10.1055/s-0042-1751361.

Nguyen, G.-N., Jordan, E.N., and Kayser, O. Synthetic strategies for rare cannabinoids derived from Cannabis sativa. J Nat Products 2022, DOI: 10.1021/acs.jnatprod.2c00155.

Jordan, E.N., Nguyen, G.-N., Piechot, A., and Kayser, O. Cannabinoids as new drug candidates for the treatment of glaucoma. Planta Med 2022, 88: 1-18. DOI: 10.1055/a-1665-3100.